Page 58 - Read Online

Page 425 Aydin et al. J Transl Genet Genom. 2025;9:406-26 https://dx.doi.org/10.20517/jtgg.2025.108

canine model of Duchenne muscular dystrophy. Hum Gene Ther. 2019;30:535-43. DOI PubMed PMC
85. Zhao B, Wang L, Hu P, et al. Fusing higher and lower-order biological information for drug repositioning via graph representation
learning. IEEE Trans Emerg Topics Comput. 2024;12:163-76. DOI
86. Agatsuma T, Ogawa H, Akasaka K, et al. Halohydrin and oxime derivatives of radicicol: synthesis and antitumor activities. Bioorg
Med Chem. 2002;10:3445-54. DOI
87. Schulte TW, Akinaga S, Murakata T, et al. Interaction of radicicol with members of the heat shock protein 90 family of molecular
chaperones. Mol Endocrinol. 1999;13:1435-48. DOI
88. Zhou H, Qiao K, Gao Z, Vederas JC, Tang Y. Insights into radicicol biosynthesis via heterologous synthesis of intermediates and
analogs. J Biol Chem. 2010;285:41412-21. DOI PubMed PMC
89. Rice CA, Colon BL, Chen E, Hull MV, Kyle DE. Discovery of repurposing drug candidates for the treatment of diseases caused by
pathogenic free-living amoebae. PLoS Negl Trop Dis. 2020;14:e0008353. DOI PubMed PMC
90. Islam T, Rahman MR, Aydin B, Beklen H, Arga KY, Shahjaman M. Integrative transcriptomics analysis of lung epithelial cells and
identification of repurposable drug candidates for COVID-19. Eur J Pharmacol. 2020;887:173594. DOI PubMed PMC
91. Turanli B, Karagoz K, Bidkhori G, et al. Multi-omic data interpretation to repurpose subtype specific drug candidates for breast
cancer. Front Genet. 2019;10:420. DOI PubMed PMC
92. Sail V, Hadden MK. Chapter eighteen - notch pathway modulators as anticancer chemotherapeutics. Annu Rep Med Chem.
2012;47:267-80. DOI
93. Dutta R, Khalil R, Green R, Mohapatra SS, Mohapatra S. Withania somnifera (Ashwagandha) and withaferin a: potential in
integrative oncology. Int J Mol Sci. 2019;20:5310. DOI PubMed PMC
94. Straughn AR, Kakar SS. Withaferin a: a potential therapeutic agent against COVID-19 infection. J Ovarian Res. 2020;13:79. DOI
PubMed PMC
95. Das R, Rauf A, Akhter S, et al. Role of Withaferin a and its derivatives in the management of alzheimer’s disease: recent trends and
future perspectives. Molecules. 2021;26:3696. DOI PubMed PMC
96. Berghe W, Sabbe L, Kaileh M, Haegeman G, Heyninck K. Molecular insight in the multifunctional activities of Withaferin A.
Biochem Pharmacol. 2012;84:1282-91. DOI PubMed
97. Radzka J, Łapińska Z, Szwedowicz U, Gajewska-Naryniecka A, Gizak A, Kulbacka J. Alternations of NF-κB signaling by natural
compounds in muscle-derived cancers. Int J Mol Sci. 2023;24:11900. DOI PubMed PMC
98. Zhang W, Zhuang X, Wu C, et al. Apigenin inhibits tumor angiogenesis by hindering microvesicle biogenesis via ARHGEF1. Cancer
Lett. 2024;596:216961. DOI
99. Dormán G, Flachner B, Hajdú I, András C. Target identification and polypharmacology of nutraceuticals. In: Gupta RC, Lall R,
Srivastava A, Editors. Nutraceuticals. Elsevier Inc.; 2016. pp. 263-86. DOI
100. Jantan I, Haque MA, Arshad L, Harikrishnan H, Septama AW, Mohamed-Hussein ZA. Dietary polyphenols suppress chronic
inflammation by modulation of multiple inflammation-associated cell signaling pathways. J Nutr Biochem. 2021;93:108634. DOI
PubMed
101. Yang M, Lin L, Scartelli C, et al. Inhibition of Sars-Cov-2 viral replication and in vivo thrombus formation by a novel plant
flavonoid. Blood. 2021;138:3144. DOI
102. Farhan M. The promising role of polyphenols in skin disorders. Molecules. 2024;29:865. DOI PubMed PMC
103. Laoudj-Chenivesse D, Carnac G, Bisbal C, et al. Increased levels of adenine nucleotide translocator 1 protein and response to
oxidative stress are early events in facioscapulohumeral muscular dystrophy muscle. J Mol Med. 2005;83:216-24. DOI
104. Hangül C, Karaüzüm SB, Akkol EK, et al. Promising perspective to facioscapulohumeral muscular dystrophy treatment:
nutraceuticals and phytochemicals. Curr Neuropharmacol. 2021;19:2276-95. DOI
105. Sethi G, Ahn KS, Pandey MK, Aggarwal BB. Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses
invasion of tumor cells by inhibiting NF-κB-regulated gene products and TAK1-mediated NF-κB activation. Blood. 2007;109:2727-
35. DOI PubMed
106. Cohen TV, Cohen JE, Partridge TA. Myogenesis in dysferlin-deficient myoblasts is inhibited by an intrinsic inflammatory response.
Neuromuscul Disord. 2012;22:648-58. DOI PubMed PMC
107. Cascão R, Fonseca JE, Moita LF. Celastrol: a spectrum of treatment opportunities in chronic diseases. Front Med. 2017;4:69. DOI
PubMed PMC
108. Xu S, Feng Y, He W, et al. Celastrol in metabolic diseases: progress and application prospects. Pharmacol Res. 2021;167:105572.
DOI
109. Wang Z, Zhai Z, Du X. Celastrol inhibits migration and invasion through blocking the NF-κB pathway in ovarian cancer cells. Exp
Ther Med. 2017;14:819-24. DOI PubMed PMC
110. Gwag T, Ha K, Shin H, et al. Application of a heat shock protein inducer to remedy for an atrophied muscle cell: a basic research for
ISS/JEM onboard experiment. Trans JSASS Aerospace Tech Japan. 2014;12:Pp_7-Pp_10. DOI
111. Faust K, Gehrke S, Yang Y, Yang L, Beal MF, Lu B. Neuroprotective effects of compounds with antioxidant and anti-inflammatory
properties in a Drosophila model of Parkinson’s disease. BMC Neurosci. 2009;10:109. DOI
112. Wu M, Zhang Y. Integrated bioinformatics, network pharmacology, and artificial intelligence to predict the mechanism of celastrol
against muscle atrophy caused by colorectal cancer. Front Genet. 2022;13:1012932. DOI PubMed PMC
113. Kori M, Arga KY, Mardinoglu A, Turanli B. Repositioning of anti-inflammatory drugs for the treatment of cervical cancer sub-types.